A detailed history of Squarepoint Ops LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 161,869 shares of RNA stock, worth $5.15 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
161,869
Previous 115,508 40.14%
Holding current value
$5.15 Million
Previous $4.72 Million 57.57%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $1.73 Million - $2.23 Million
46,361 Added 40.14%
161,869 $7.43 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $1.18 Million - $2.11 Million
51,743 Added 81.15%
115,508 $4.72 Million
Q1 2024

May 15, 2024

BUY
$9.16 - $25.52 $6,741 - $18,782
736 Added 1.17%
63,765 $1.63 Million
Q4 2023

Feb 14, 2024

BUY
$4.87 - $9.37 $71,316 - $137,214
14,644 Added 30.27%
63,029 $570,000
Q2 2023

Aug 14, 2023

BUY
$10.62 - $17.34 $100,263 - $163,706
9,441 Added 24.24%
48,385 $536,000
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $105,301 - $175,959
6,860 Added 21.38%
38,944 $597,000
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $322,765 - $727,023
32,084 New
32,084 $711,000
Q1 2022

May 16, 2022

SELL
$14.2 - $23.78 $160,076 - $268,071
-11,273 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.4 - $28.66 $229,969 - $323,084
11,273 New
11,273 $268,000
Q3 2021

Nov 15, 2021

SELL
$18.16 - $25.21 $426,596 - $592,208
-23,491 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$19.62 - $29.26 $213,367 - $318,202
10,875 Added 86.2%
23,491 $580,000
Q1 2021

May 17, 2021

BUY
$20.28 - $28.15 $57,656 - $80,030
2,843 Added 29.09%
12,616 $275,000
Q4 2020

Feb 16, 2021

BUY
$24.73 - $35.12 $241,686 - $343,227
9,773 New
9,773 $249,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.66B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.